Loading...
NPI 1538268438 · Las Vegas, NV · Medical Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Fadi Braiteh is a medical oncology physician provider located in Las Vegas, Nevada. This profile covers 75 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Fadi Braiteh |
| Address | 3730 S Eastern Ave |
| City | Las Vegas |
| State | NV |
| ZIP | 89169 |
| Taxonomy | Medical Oncology Physician |
| NPI Enumerated | September 21, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.5M |
| Medicaid | $30.1K |
FADI BRAITEH presents as an outpatient medical oncology practice with a code mix dominated by advanced imaging, immunotherapy infusions, chemotherapy administration, and high-complexity office visits. Key Medicare activity includes PET/CT imaging (78815) and checkpoint inhibitor infusions (J9271, J9299), supported by chemotherapy administration codes (96413, G0498) and frequent high-level E/M codes (99215, 99214), which together portray an infusion-and-imaging–centric oncology operation.
Medicare revenue is concentrated: the provider reports $1.5M in total Medicare revenue and the precomputed top three Medicare codes (78815, J9271, J9299) collectively account for 59.7% of that Medicare revenue. Individually these top Medicare contributors are $305K for 78815, $301K for J9271, and $256.3K for J9299, indicating a mix of imaging and high-cost drug administration drives most Medicare dollars.
Medicaid billing is narrowly concentrated and modest in scale: total Medicaid revenue is $30.1K and the precomputed top three Medicaid codes (99215, 99214, 96413) account for 100.0% of Medicaid revenue. The Medicaid top-line contributors are $15.8K for 99215, $11.4K for 99214, and $2.9K for 96413, showing Medicaid receipts are nearly entirely from E/M visits and a small amount of chemotherapy.
Payer mix is heavily Medicare-skewed: the provider reports $1.5M in Medicare revenue versus $30.1K in Medicaid revenue, so Medicare is the dominant payer funding the practice’s services while Medicaid represents a very small fraction of total reported revenue. This suggests the provider’s patient and reimbursement mix is oriented toward Medicare beneficiaries and commercially reimbursed infusion/imaging pathways rather than state Medicaid volumes.
Competitive standing across Medicare codes is mixed: the provider is an extreme outlier for high-complexity office visits (99215 ranks #709 of 145531 nationally, 100th percentile, described as an "extreme outlier"), indicating unusually high national volume of high-complexity E/Ms. In contrast, the immunotherapy drug codes show more modest national positions (J9271 ranks #1520 of 1841, 16th percentile; J9299 ranks #337 of 505, 33rd percentile), and 78815 imaging is at the 87th percentile (#831 of 6566) consistent with typical to above-typical imaging volume for a cancer practice.
State-level (Medicaid) competitive signals are modest: Medicaid 99215 ranks #153 of 363 in-state (58th percentile) and 99214 ranks in the 33rd percentile, both described as typical volumes, while Medicaid chemotherapy (96413) ranks #16 of 19 in-state (17th percentile), indicating relatively low Medicaid chemotherapy throughput compared with a small set of in-state peers. These positions imply stronger Medicare-facing activity than Medicaid-facing infusion volume.
Operational implications from ancillary and supportive-code patterns suggest on-site infusion and monitoring capacity. High claim counts and revenues for administration/support codes and supportive drugs — for example G0498 (112 claims, $15.7K, 93rd percentile), J0881 (18.2K claims, $36.4K, 69th percentile), and frequent lab and phlebotomy codes (80053: 928 claims; 36415: 976 claims) — are consistent with structured infusion workflows, routine laboratory monitoring, and repeated supportive medication use. This combination supports an outpatient infusion center model tied to oncology care pathways.
The provider has an established tenure on file, with NPI enumeration dated 2006-09-21 (~20 years ago), which together with consistent Medicare billing patterns suggests a stable, long-running oncology practice rather than a recent entrant to the market.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
75 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 240 | $1,260 | $305K |
| J9271 | Injection, pembrolizumab, 1 mg | 7,000 | $40 | $301K |
| J9299 | Injection, nivolumab, 1 mg | 10,680 | $20 | $256.3K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 730 | $130 | $96.8K |
| J0897 | Injection, denosumab, 1 mg | 4,380 | $20 | $78.8K |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | 150 | $490 | $74.8K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 230 | $280 | $64.9K |
| A9587 | Gallium ga-68, dotatate, diagnostic, 0.1 millicurie | 760 | $50 | $37.8K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 370 | $100 | $36.5K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 18,220 | $1 | $36.4K |
Showing 1–10 of 75
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 75 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
75 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 32 | 40 | 13,000 | $40 | $625.8K |
| J9299 | 8 | 10 | 14,400 | $20 | $362K |
| A9595 | 3 | 10 | 150 | $490 | $109.6K |
| J0897 | 29 | 70 | 3,630 | $20 | $94.6K |
| 78815 | 5 | 60 | 60 | $930 | $80.4K |
| J0881 | 15 | 30 | 17,400 | $1 | $49.5K |
| 82306 | 7 | 30 | 80 | $30 | $41.9K |
| A9587 | 1 | 10 | 760 | $50 | $37.5K |
| 96413 | 16 | 70 | 210 | $100 | $23.7K |
| A9552 | 5 | 50 | 40 | $240 | $22.7K |
Showing 1–10 of 75
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 130 | $130 | $15.8K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 120 | $100 | $11.4K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 30 | $110 | $2.9K |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 16 | 20 | 240 | $90 | $189.3K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,510 | 2,250 | 290 | $60 | $138K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 153 | 360 | 90 | $70 | $28.2K |
Other providers in the same ZIP code as Fadi Braiteh, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.